Literature DB >> 7493437

Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations.

A Ballinger1, L McLoughlin, S Medbak, M Clark.   

Abstract

1. Intravenous infusions of the brain/gut hormone, cholecystokinin, have been shown to reduce food intake in a subsequent test meal. However, in previous studies the doses administered were large and likely to have produced plasma concentrations far in excess of the normal post-prandial range. 2. In this study cholecystokinin-8 was infused intravenously to six healthy subjects in doses that reproduced physiological post-prandial concentrations. Plasma concentrations of cholecystokinin were measured using a novel sensitive and specific radioimmunoassay. The effect of cholecystokinin-8 infusion on subsequent food intake in a standard test meal was compared with the effect of saline infusion in the same subjects. 3. Food intake (mean +/- SEM) was significantly less during cholecystokinin (5092 +/- 665 kJ) than during saline infusion (6418 +/- 723 kJ, P = 0.03). During cholecystokinin infusion, plasma concentrations increased from 0.45 +/- 0.06 pmol/l to 7.28 +/- 2.43 pmol/l immediately before the meal. With saline infusion there was no premeal increase in plasma cholecystokinin concentration. 4. This paper describes a novel radioimmunoassay for measurement of plasma concentrations of cholecystokinin. Using this assay we have demonstrated that cholecystokinin is important in control of satiety in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493437     DOI: 10.1042/cs0890375

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  19 in total

Review 1.  Neuroendocrine regulation of eating behavior.

Authors:  R Vettor; R Fabris; C Pagano; G Federspil
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

2.  Gastric leptin.

Authors:  A Ballinger
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 3.  Clinical uses of gut peptides.

Authors:  J Geoghegan; T N Pappas
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

5.  Appetite-Related Gut Peptides in Obesity and Binge Eating Disorder.

Authors:  Allan Geliebter; Christopher N Ochner; Roni Aviram-Friedman
Journal:  Am J Lifestyle Med       Date:  2008-07-01

Review 6.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 7.  Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity.

Authors:  Gary D Miller
Journal:  Am J Lifestyle Med       Date:  2017-06-23

Review 8.  The gut and food intake: an update for surgeons.

Authors:  E Näslund; P M Hellström; J G Kral
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

9.  CCK-58 elicits both satiety and satiation in rats while CCK-8 elicits only satiation.

Authors:  Joost Overduin; James Gibbs; David E Cummings; Joseph R Reeve
Journal:  Peptides       Date:  2014-01-24       Impact factor: 3.750

10.  Fatty acids stimulate cholecystokinin secretion via an acyl chain length-specific, Ca2+-dependent mechanism in the enteroendocrine cell line STC-1.

Authors:  J T McLaughlin; R B Lomax; L Hall; G J Dockray; D G Thompson; G Warhurst
Journal:  J Physiol       Date:  1998-11-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.